Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05798780
Other study ID # MCC-22330
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 6, 2023
Est. completion date January 2025

Study information

Verified date May 2024
Source H. Lee Moffitt Cancer Center and Research Institute
Contact Sylvia Crowder, PhD
Phone 813-745-6849
Email Sylvia.Crowder@moffitt.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to design a physical activity and dietary intervention for head and neck cancer patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - >18 years old - Newly diagnosed tumors of the oral cavity, oropharynx, hypopharynx, or larynx - No documented or observable psychiatric or neurological disorders that would interfere with study participation (e.g., dementia, psychosis) - Able to speak and read English - Able to consume food orally - Willing to consume an alternative Mediterranean diet - Scheduled to receive treatment with radiation or chemoradiation - Screened via the Physical Activity Readiness Questionnaire (PAR-Q+) with medical clearance of treating physicians, as necessary - Able to provide informed consent Exclusion Criteria: - Women who are pregnant - Head and Neck Cancer not the primary diagnosis - Patients scheduled to receive surgery - Patients on enteral or parental nutrition

Study Design


Intervention

Behavioral:
ENHANCE Intervention - Exercise and Nutrition
During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.
ENHANCE Intervention - Nutrition Only
During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.

Locations

Country Name City State
United States Moffitt Cancer Center Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Recruited - Feasibility The study will be deemed feasible if = 60% of eligible participants are enrolled 12 Months
Primary Number of Participants who Complete Questionnaire - Retention - Feasibility The study will be deemed feasible if = 70% of participants complete post intervention questionnaire. 12 weeks
Primary Participant Satisfaction of Timeline - Feasibility The study will be deemed feasible if = 70% of participants like the timing of the intervention using a likert scale (scale range Strongly agree to Strongly disagree) 12 weeks
Primary Participant Average Attendance - Assessment Completion - Adherence Participant assessment completion will be deemed successful if participant average attendance is =10 weeks of sessions (out of 12) 12 weeks
Primary Number of Participants who Complete Task/Goals - Adherence Study adherence will be deemed successful if =70% of participants report weekly tasks/goals adherence (e.g., gym and diet) 12 weeks
Primary Participant Satisfaction Assessed with 5 Point Scale - Acceptability Participants satisfaction will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up. 12 weeks
Primary Participant Intent to Continue Assessed with 5 Point Scale - Acceptability Participants intent to continue will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up. 12 weeks
Primary Participant Knowledge Gained Assessed with 5 Point Scale - Acceptability Participants knowledge gained will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Completed NCT00158678 - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Phase 3
Completed NCT04567082 - Proteome- and Methylation Profiles in Oropharyngeal Cancer
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Completed NCT03435471 - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer N/A
Completed NCT05055206 - Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers N/A
Recruiting NCT04359199 - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Active, not recruiting NCT02908477 - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Phase 3
Active, not recruiting NCT00232960 - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC N/A
Completed NCT05698667 - Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer N/A
Recruiting NCT05757817 - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Completed NCT03342378 - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Active, not recruiting NCT03416153 - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer Phase 2
Terminated NCT01066741 - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Phase 3
Completed NCT03418792 - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx N/A
Recruiting NCT06088381 - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Phase 2